QIAGEN N.V. (NYSE:QGEN) will collaborate with Amgen (NASDAQ:AMGN) to develop a tissue-based companion diagnostic for cancer candidate AMG 510. The initial work will focus on non-small cell lung cancer but the agreement allows for development for other indications.
Financial terms are not disclosed.
Now read: Amgen Inc.: Not Cheap At Present »
Try Seeking Alpha PREMIUM for unlimited analysis on QGEN